Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/33139
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChompoonuch Sawaengsaken_US
dc.contributor.authorYasuko Morien_US
dc.contributor.authorKoichi Yamanishien_US
dc.contributor.authorAmpol Mitrevejen_US
dc.contributor.authorNuttanan Sinchaipaniden_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherKobe University School of Medicineen_US
dc.contributor.otherNational Institute of Biomedical Innovationen_US
dc.date.accessioned2018-11-09T01:47:49Z-
dc.date.available2018-11-09T01:47:49Z-
dc.date.issued2014-01-01en_US
dc.identifier.citationAAPS PharmSciTech. Vol.15, No.2 (2014), 317-325en_US
dc.identifier.issn15309932en_US
dc.identifier.other2-s2.0-84898010025en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84898010025&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/33139-
dc.description.abstractSubunit/split influenza vaccines are less reactogenic compared with the whole virus vaccines. However, their immunogenicity is relatively low and thus required proper adjuvant and/or delivery vehicle for immunogenicity enhancement. Influenza vaccines administered intramuscularly induce minimum, if any, mucosal immunity at the respiratory mucosa which is the prime site of the infection. In this study, chitosan (CS) nanoparticles were prepared by ionic cross-linking of the CS with sodium tripolyphosphate (TPP) at the CS/TPP ratio of 1:0.6 using 2 h mixing time. The CS/TPP nanoparticles were used as delivery vehicle of an intranasal influenza vaccine made of hemagglutinin (HA)-split influenza virus product. Innocuousness, immunogenicity, and protective efficacy of the CS/TPP-HA vaccine were tested in influenza mouse model in comparison with the antigen alone vaccine. The CS/TPP-HA nanoparticles had required characteristics including nano-sizes, positive charges, and high antigen encapsulation efficiency. Mice that received two doses of the CS/TPP-HA vaccine intranasally showed no adverse symptoms indicating the vaccine innocuousness. The animals developed higher systemic and mucosal antibody responses than vaccine made of the HA-split influenza virus alone. The CS/TPP-HA vaccine could induce also a cell-mediated immune response shown as high numbers of IFN-γ-secreting cells in spleens while the HA vaccine alone could not. Besides, the CS nanoparticle encapsulated HA-split vaccine reduced markedly the influenza morbidity and also conferred 100% protective rate to the vaccinated mice against lethal influenza virus challenge. Overall results indicated that the CS nanoparticles invented in this study is an effective and safe delivery vehicle/adjuvant for the influenza vaccine. © 2013 American Association of Pharmaceutical Scientists.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84898010025&origin=inwarden_US
dc.subjectAgricultural and Biological Sciencesen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleChitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccineen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.1208/s12249-013-0058-7en_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.